https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31068 Wed 24 Nov 2021 15:51:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51839 Wed 20 Sep 2023 16:12:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26567 TM GX Human Inflammation Kit 2. Results: Following the interventions, clinical characteristics and plasma IL-6 and CRP were unchanged. Sputum neutrophil proportion and absolute count was increased and macrophage proportion decreased by rosuvastatin (P = 0.020 and P = 0.015; respectively). Rosuvastatin increased LTB4R and decreased CXCL10 and AGER gene expression in white blood cells. The addition of lycopene and omega-3 fatty acids decreased LTB4R and increased CXCL10 to basal levels, whilst combined use of interventions increased ALOX15 blood gene expression. Conclusion This study shows that rosuvastatin, omega-3 fatty acids and lycopene have some anti-inflammatory effects systemically, but rosuvastatin may increase airway neutrophils, which would be undesirable in COPD patients, warranting further investigation.]]> Wed 02 Mar 2022 14:27:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43636 Tue 27 Sep 2022 09:39:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54436 Tue 27 Feb 2024 13:49:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39820 Tue 26 Jul 2022 11:33:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52374 Tue 10 Oct 2023 14:37:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45086 25 billion CFU) and placebo. Plasma SCFA, sputum cell counts and inflammatory gene expression, asthma control gut microbiota, adverse events including gastrointestinal symptoms were measured. Findings: There was no difference in change in total plasma SCFA levels (μmol/L) in the placebo versus soluble fibre (Δmedian [95% CI] 16·3 [−16·9, 49·5], p = 0·335) or soluble fibre+probiotic (18·7 [−14·5, 51·9], p = 0·325) group. Following the soluble fibre intervention there was an improvement in the asthma control questionnaire (ACQ6) (∆median (IQR) -0·35 (−0·5, −0·13), p = 0·006), sputum %eosinophils decreased (−1.0 (−2·5, 0), p = 0·006) and sputum histone deacetylase 9 (HDAC9) gene expression decreased (−0.49 (−0.83, −0.27) 2^-ΔCt, p = .008). Individual bacterial operational taxonomic units changed following both inulin and inulin+probiotic arms. Interpretation: Soluble fibre supplementation for 7 days in adults with asthma did not change SCFA levels. Within group analysis showed improvements in airway inflammation, asthma control and gut microbiome composition following inulin supplementation and these changes warrant further investigation, in order to evaluate the potential of soluble fibre as a non-pharmacological addition to asthma management.]]> Thu 27 Oct 2022 14:06:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50862 Thu 17 Aug 2023 11:36:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27185 Sat 24 Mar 2018 07:31:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48193 Sat 11 Mar 2023 12:30:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48173 Sat 11 Mar 2023 12:23:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39780 Mon 25 Jul 2022 11:26:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48926 Mon 01 May 2023 08:56:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30780 Fri 03 Dec 2021 10:34:35 AEDT ]]>